Skip to main content
. 2021 May 21;13:4077–4086. doi: 10.2147/CMAR.S305321

Figure 1.

Figure 1

Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS) according to the use of metformin and other OADs.